Hepatitis B virus (HBV) infection is a major challenge in patients undergoing hematopoietic stem cell transplantation. In particular, hepatitis B surface antigen (HBsAg) carriers and patients with a latent infection are at high risk for viral reactivation after transplantation.
1,2 Acute infection may also be acquired prior to the transplantation procedure from transfusion of infected blood products. After myeloablative and during immunosuppressive therapy most transplanted patients with HBV infection have only mild elevations in transaminases, due to the suppression of host cellular immune responses which cause most of the hepatocellular damage. However, during this period the viral load in the liver progressively increases, which can lead to severe hepatitis at the time of immune reconstitution. Fulminant hepatic failure with a fatal outcome occurs in approximately 12% of HBV-infected transplant recipients. 1 Lamivudine, an oral nucleoside analogue, profoundly suppresses serum HBV DNA levels in immunocompetent patients with chronic hepatitis B, although HBsAg seroconversion rarely occurs. 3, 4 This drug has also been used sporadically to prevent viral reactivation in HBsAg carriers and in patients with anti-HBs antibodies (Abs) receiving prolonged immunosuppressive therapy 5 or undergoing bone marrow transplantation. [6] [7] [8] [9] We report on the use of lamivudine to treat acute HBV infection, which presented during the conditioning for allogeneic stem cell transplantation. The patient was a 34-year-old woman with acute myeloblastic leukemia -M2, diagnosed in June 2001. At that time, she was negative for HBsAg and anti-HBs antibody. She was treated with two cycles of induction chemotherapy with daunorubycin, Ara-C and etoposide, followed by consolidation with intermediate dose Ara-C and Mitoxantrone. In October 2001, she received an allogeneic peripheral blood stem cell transplant from her HLA-identical sister ( Figure 1 ). The donor was HBsAg and anti-HBs antibody negative. During conditioning with busulfan and cyclophosphamide, the patient developed acute icteric hepatitis with peak ALT and AST values of 1350 and 600 IU/l, respectively. Serological analyses showed that she had become HBsAg positive, anti-HBs Ab negative, anti-HBc IgM positive, HBeAg positive, antiHBe Ab negative and anti-HCV Ab negative, indicating that she had acquired an acute HBV infection from one of the transfusions received during the period of chemotherapy. Treatment with oral lamivudine was started immediately at a dose of 100 mg/day. GVHD prophylaxis was cyclosporine A (CsA) and short-course methotrexate. Enoxaparin and fresh frozen plasma were used for VOD prophylaxis, and hematopoietic engraftment was documen- ted on day 19. Subsequently, the transaminases gradually decreased, with a second flare about 2 months after the initiation of lamivudine treatment, and then fell again to values less than two times normal. HBsAg was still present 4 months after the transplant. CsA was discontinued 2 months later, but prednisone (2 mg/kg) was started after 3 weeks because of the appearance of mild chronic GVHD of the skin and oral cavity. During this period the patient became HBsAg negative, which was confirmed 1 month later when seroconversion to anti-HBs Ab was documented.
To our knowledge, this is the first report in which lamivudine was used to treat acute HBV infection in a patient undergoing allogeneic peripheral blood stem cell transplantation. Our main concern was that unopposed viral replication during the period of immunosuppression would lead to massive infection of the liver and fulminant hepatic necrosis at the time of cessation of immunosuppressive therapy and immune reconstitution. For this reason, the patient was closely monitored when CsA was tapered and discontinued. However, no serious liver dysfunction occurred, and the transaminase levels remained only slightly elevated. Moreover, HBsAg seroconversion was documented shortly afterward, even though the patient was receiving prednisone for chronic GVHD during this period. Considering the lack of serious side effects and the apparent efficacy, lamivudine appears to be a promising drug to treat or prevent active HBV infection in patients undergoing hematopoietic stem cell transplantation. 
